Becton Dickinson Q1 Revenue $5.25 B and Record 25% Operating Margin
Total Q1 FY2026 revenue for Becton Dickinson reached $5.25 billion, up 1.6% reported, with New BD segment revenue rising 3.5% (2.5% FX-neutral) to $4.49 billion driven by Connected Care’s 5.5% increase and Interventional’s $1.33 billion, up 5.8%. Adjusted operating margin hit a record 25.0% in FY2025 and management aims to sustain a 25% margin floor in FY2026 despite a 370 basis point tariff headwind.
1. Q1 FY2026 Performance
Becton Dickinson reported total revenue of $5.25 billion in Q1 FY2026, up 1.6% as reported. The New BD perimeter generated $4.49 billion, a 3.5% increase reported (2.5% currency-neutral), led by a 5.5% rise in Connected Care and $1.33 billion in Interventional revenue, up 5.8%.
2. Margin Expansion and Cost Initiatives
The company delivered a record 25.0% adjusted operating margin in FY2025, expanding roughly 80 basis points annually since FY2023. A $200 million cost-out program (75% executed) and BD Excellence productivity gains of 8% in Q1 fully offset an estimated 370 basis point tariff drag.
3. Growth Platforms and Acquisitions
Advanced Patient Monitoring, acquired for $4.2 billion, achieved high-single-digit growth while pharmacy automation grew at double-digit rates. The BioPharma Systems unit rose 2.7%, led by double-digit growth in GLP-1 prefillable syringes and autoinjectors now contracted with over 80 molecules.
4. Spin-Off and Capital Strategy
Post spin-off, BD has reduced manufacturing sites from over 90 to fewer than 50 and deployed $4 billion in proceeds through an ASR and debt tender, cutting share count by 56% and saving approximately $60–70 million in interest. Net leverage stands at 2.9x with a target of 2.5x.